ReviewNature reviews. Cancer2015
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Abstract readReview
In one paragraph
Review in Nature reviews. Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 733 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
733citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
733 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Integrative Meta-Analysis Identifies Epithelial-Mesenchymal Transition Gene Signatures as Key Determinants of Ovarian Cancer Progression and Treatment Outcome.International journal of molecular sciences · 2026Pooled it
- Artificial intelligence for ovarian cancer diagnosis via ultrasound: a systematic review and quantitative assessment of model performance.Frontiers in artificial intelligence · 2025Pooled it
- Genotype-driven variations in lncRNA expression underlie predisposition to high-grade serous ovarian cancer.Journal of advanced research · 2026Article
- Review
- Prevalence of BRCA1/2 variants in an Ovarian Cancer Cohort: outcomes from a Nationwide Testing Program.European journal of human genetics : EJHG · 2026Article
- HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution.Cancer discovery · 2026Article
- The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.Nature aging · 2026Article
- Immunological and prognostic impact of NRF2 in high grade serous ovarian cancer.Genes and immunity · 2026Article
- Progesterone induces steroidome and lipidome remodeling in a BRCA-resembling mouse model of high-grade serous ovarian cancer.Translational oncology · 2026Article
- Carboxylesterase 1 is a core metabolic vulnerability of platinum-resistant high-grade serous ovarian carcinoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Prognostic Value of Morphological Characteristics and Immune Microenvironment in High-Grade Serous Cancer (HGSC).Cancers · 2026Article
- Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours.Nature communications · 2026Article
- Article
- Patient-derived organoids in gynaecological cancers: emerging tools for therapy and disease modelling.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Podocalyxin may be down-regulated by progesterone in high grade serous ovarian cancer spheroids to increase responsiveness to carboplatin and NK cells.BMC cancer · 2026Article
- Biomimetic fusion nanosystem from ginger exosomes and tumor cell membranes: boosting PLK1-targeted therapy in BRCA-heterogeneous HGSOC.Journal of nanobiotechnology · 2026Article
- Ciliated Cells Drive Critical STING-Mediated Tumor Suppression in the Fallopian Tube Epithelium.Cancer research · 2026Article
- Development and validation of pathomics signature for predicting prognosis of advanced high-grade serous ovarian carcinoma patients after platinum-based chemotherapy.Scientific reports · 2026Article
- Conserved host genes act as anchors for fast-evolving piRNA clusters via promoter hijacking.Research square · 2026Article
673 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
David D BowtellCancer Genomics and Genetics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria 8006, Australia; and the Kinghorn Cancer Centre, Garvan Institute for Medical Research, Darlinghurst, Sydney, 2010 New South Wales, Australia.
Steffen BöhmBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK.
Ahmed A AhmedNuffield Department of Obstetrics and Gynaecology and the Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK.
Paul-Joseph AspuriaCedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.
Robert C BastMD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
Valerie BeralUniversity of Oxford, Headington, Oxford, OX3 7LF, UK.
Jonathan S BerekStanford University, Stanford, California 94305, USA.
Michael J BirrerMassachusetts General Hospital, Boston, Massachusetts 02114 USA.
Sarah BlagdenOvarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
Michael A BookmanArizona Oncology, Tucson, Arizona 85711, USA.
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
Katherine B ChiappinelliThe Sidney Kimmel Cancer Center at John Hopkins University, Baltimore, Maryland 21287, USA.
Filipe Correia MartinsCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, UK.
George CoukosUniversity Hospital of Lausanne, Lausanne, Switzerland.
Ronny DrapkinUniversity of Pennsylvania, Penn Ovarian Cancer Research Center, Philadelphia, Pennsylvania 19104, USA.
Richard EdmondsonUniversity of Manchester, Manchester M13 9WL, UK.
Christina FotopoulouOvarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
Hani GabraOvarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
Jérôme GalonInstitut National de la Santé et de la Recherche Médicale, UMRS1138, Laboratory of Integrative Cancer Immunology, Cordeliers Research Center, Université Paris Descartes, Sorbonne Paris Cité, Sorbonne Universités, UPMC Univ Paris 06, 75006 Paris, France.
Charlie GourleyCancer Research Centre, University of Edinburgh, Edinburgh EH4 2XR, UK.
Valerie HeongWalter and Eliza Hall Institute, Parkville, Victoria 3052, Australia.
David G HuntsmanUniversity of British Columbia, Departments of Pathology and Laboratory Medicine and Obstetrics and Gynecology, Faculty of Medicine, Vancouver, British Columbia V6T 2B5, Canada.
Marcin IwanickiHarvard Medical School, Boston, Massachusetts 02115, USA.
Beth Y KarlanCedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.
Allyson KayeOvarian Cancer Action, London NW1 OJH, UK.
Ernst LengyelUniversity of Chicago, Chicago, Illinois 60637, USA.
Douglas A LevineMemorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Karen H LuMD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
Iain A McNeishUniversity of Glasgow, Glasgow G61 1QH, UK.
Usha MenonWomen's Cancer, Institute for Women's Health, University College London, London WC1E 6BT, UK.
Steven A NarodWomen's College Research Institute, Toronto, Ontario M5G 1N8, Canada.
Brad H NelsonBritish Columbia Cancer Agency, Victoria, British Columbia V8R 6V5, Canada.
Kenneth P NephewIndiana University School of Medicine &Simon Cancer Center, Bloomington, IN 47405-4401, USA.
Paul PharoahUniversity of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
Daniel J PowellUniversity of Pennsylvania, Philadelphia, PA 19104-5156, USA.
Pilar RamosTranslational Genomics Research Institute (Tgen), Phoenix, Arizona 85004, USA.
Iris L RomeroUniversity of Chicago, Chicago, Illinois 60637, USA.
Clare L ScottWalter and Eliza Hall Institute, Parkville, Victoria 3052, Australia.
Anil K SoodMD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030-4009, USA.
Euan A StronachOvarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
Frances R BalkwillBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK.
Funding
Regulation of Adhesion and Proteolysis in Ovarian CancerR01CA111882 · NCI · UNIVERSITY OF CHICAGO · PI LENGYEL, ERNST · 2006 to 2016
$2.8MA Universal Approach to Personalized Adoptive T cell Therapy of CancerR01CA168900 · NCI · UNIVERSITY OF PENNSYLVANIA · PI POWELL, DANIEL J. · 2012 to 2016
$1.6MAn Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian CancerR01CA182832 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MATEI, DANIELA E, NEPHEW, KENNETH P · 2014 to 2018
$1.6MCancer Research UK 15601Cancer Research UK 16354Cancer Research UK 16491Cancer Research UK 16561Chief Scientist Office ETM/92Chief Scientist Office SCD/11Medical Research Council G0501974Medical Research Council G0902418Medical Research Council MR/K02700X/1NCI NIH HHS R01 CA111882NCI NIH HHS R01 CA168900NCI NIH HHS R01 CA182832
Abstract
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
Indexed as
Cystadenocarcinoma, SerousFemaleHumansNeoplasm GradingOvarian NeoplasmsPrognosisSurvival Rate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.